Jennifer A. Jones MD, PhD; Marshall J. Shuler, MD; Barrett J. Zlotoff, MD
Dr. Jones is from the Department of Medicine, Harbor-UCLA Medical Center, Torrance. Drs. Shuler and Zlotoff are from the Department of Dermatology, University of New Mexico Health Science Center, Albuquerque. Dr. Shuler currently is from the University of South Carolina School of Medicine, Greenville.
The authors report no conflict of interest.
Correspondence: Barrett J. Zlotoff, MD, Department of Dermatology, University of New Mexico Health Science Center, 1021 Medical Arts Ave NE, Albuquerque, NM 87102 (bzlotoff@salud.unm.edu).
Identification of the causative drug can be difficult in LDE, as timing of the eruption can vary. The latent period has been reported to range from a few months to 1 to 2 years.15 Additionally, the clinical picture is often complicated in patients with a history of different drug dosages or multiple medications. When present, the histologic features of parakeratosis and eosinophils can be clues that a lichen planus–like eruption is drug related rather than idiopathic. However, the absence of these features does not rule out a medication or environmental trigger. In this case, the time-event relationship likely indicates that the eruption was related to the levonorgestrel-releasing IUS and not triggered by other medications or not idiopathic in nature. Lichenoid drug eruptions can resolve within a few weeks or up to 2 years after drug cessation and can occasionally be complicated by partial or complete resolution and recurrence even when the drug has not been discontinued.16,17 Lichenoid drug eruptions or idiopathic lichen planus generally are treated with topical immunomodulators or corticosteroids.3
Based on the time-event relationship, morphology, distribution, and histopathologic findings, we conclude that our patient developed LDE in response to the placement of a levonorgestrel-releasing IUS. Clinicians should be aware of the possibility of LDE occurring as a rare adverse effect of these devices.